Targeted radiotherapy chelates for in situ immune modulated cancer vaccination

Patent metadata

Field	Value
Publication number	US-11730834-B2
Application number	US-202016914563-A
Country	US
Kind code	B2
Filing date	Jun 29, 2020
Priority date	Jul 25, 2016
Publication date	Aug 22, 2023
Grant date	Aug 22, 2023

Abstract

The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or by performing another method of in situ tumor vaccination. In a non-limiting example, the radioactive phospholipid metal chelate compound has the formula:wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.

First claim

The invention claimed is:

1. A method of treating a metastatic cancer in a subject, wherein the metastatic cancer comprises a primary malignant solid tumor and one or more metastatic tumors capable of causing concomitant immune tolerance, the method comprising the steps of:
(a) administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially taken up by and retained within malignant solid tumor tissue; and
(b) performing in situ tumor vaccination in the subject at the primary malignant solid tumor using one or more treatments capable of stimulating specific immune cells within the tumor microenvironment, wherein the one or more treatments comprise contacting the primary malignant solid tumor with a composition comprising one or more agents capable of stimulating specific immune cells within the tumor microenvironment;
whereby the concomitant immune tolerance caused by the metastatic tumors is prevented and the metastatic cancer is treated in the subject.

2. The method of claim 1 , wherein step (b) of performing in situ tumor vaccination in the subject further comprises treating the primary malignant solid tumor with external beam radiation therapy (xRT).

3. The method of claim 1 , wherein the immunomodulatory dose of the radioactive phospholipid metal chelate compound delivers a radiation dose of from 2 Gy to 8 Gy to the metastatic tumors.

4. The method of claim 1 , wherein the one or more agents capable of stimulating specific immune cells within the tumor microenvironment are selected from the group consisting of an immunostimulatory mAb, a pattern recognition receptor agonist, an immunostimulatory cytokine, an immune stimulatory nanoparticle, an oncolytic virus, and combinations thereof.

5. The method of claim 4 , wherein the immunostimulatory mAb is selected from the group consisting of an anti-GD2 antibody, an anti-CTLA-4 antibody, an anti-CD137 antibody, an anti-CD134 antibody, an anti-PD-1 antibody, an anti-KIR antibody, an anti-LAG-3 antibody, an anti-PD-L1 antibody, an anti-CD40 antibody, and combinations thereof.

6. The method of claim 1 , wherein the radioactive phospholipid metal chelate compound has the formula:

or a salt thereof, wherein:
R 1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days;
a is 0 or 1;
n is an integer from 12 to 30;
m is 0 or 1;
Y is selected from the group consisting of —H, —OH, —COOH, —COOX, —OCOX, and —OX, wherein X is an alkyl or an arylalkyl;
R 2 is selected from the group consisting of —N + H 3 , —N + H 2 Z, —N + HZ 2 ,k and —N + Z 3 , wherein each Z is independently an alkyl or an aryl; and
b is 1 or 2.

7. The method of claim 6 , wherein the metal isotope is selected from the group consisting of Lu-177, Y-90, Ho-166, Re-186, Re-188, Cu-67, Au-199, Rh-105, Ra-223, Ac-225, As-211, Pb-212, and Th-227.

8. The method of claim 6 , wherein the chelating agent is selected from the group consisting of 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (DO3A) and its derivatives; 1,4,7-triazacyclononane-1,4-diacetic acid (NODA) and its derivatives; 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) and its derivatives; 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and its derivatives; 1,4,7-triazacyclononane,l-glutaric acid-4,7-diacetic acid (NODAGA) and its derivatives; 1,4,7,10-tetraazacyclodecane,l-glutaric acid-4,7,10-triacetic acid (DOTAGA) and its derivatives; 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (1ETA) and its derivatives; 1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-4,11-diacetic acid (CB-1E2A) and its derivatives; diethylene triamine pentaacetic acid (DTPA), its diester, and its derivatives; 2-cyclohexyl diethylene triamine pentaacetic acid (CHX-A″-DTPA) and its derivatives; deforoxamine (DFO) and its derivatives; 1,2-[[6-carboxypyridin-2-yl]methylamino]ethane (H2dedpa) and its derivatives; and DADA and its derivatives, wherein DADA comprises the structure:

9. The method of claim 6 , wherein the chelating agent chelated to the metal atom is selected from the group consisting of:

10. The method of claim 6 , wherein the compound is selected from the group consisting of:

wherein the selected compound is chelated to the metal atom.

11. The method of claim 6 , wherein m is 1, n is an integer between 12 and 20, Y is —OCOX, —COOX or —OX, and X is —CH 2 CH 3 or —CH 3 .

12. The method of claim 6 , wherein m is 0.

13. The method of claim 6 , wherein b is 1.

14. The method of claim 6 , wherein n is 18.

15. The method of claim 6 , wherein R 2 is —N + Z 3 .

16. The method of claim 15 , wherein each Z is independently —CH 2 CH 3 or − CH 3 .

17. The method of claim 1 , wherein the radioactive phospholipid chelate compound is administered intravenously.

18. The method of claim 1 , wherein the subject is a human.

19. The method of claim 1 , wherein the metastatic cancer that is treated is selected from the group consisting of melanoma, neuroblastoma, lung cancer, adrenal cancer, colon cancer, colorectal cancer, ovarian cancer, prostate cancer, liver cancer, subcutaneous cancer, squamous cell cancer of the skin or head or neck, intestinal cancer, retinoblastoma, cervical cancer, glioma, breast cancer, pancreatic cancer, soft tissue sarcoma, Ewings sarcoma, rhabdomyosarcoma, osteosarcoma, retinoblastoma, Wilms' tumor, and pediatric brain tumors.

20. The method of claim 1 , wherein the step of contacting the primary malignant solid tumor with the composition is performed by intratumorally injecting the composition into the primary malignant solid tumor.

Assignees

• Wisconsin Alumni Res Found

Inventors

• Weichert Jamey
• Sondel Paul
• Pinchuk Anatoly
• Morris Zachary
• Otto Mario
• Bednarz Bryan
• Carlson Peter

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61K2039/585

  wherein the target is cancer · CPC title